Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / ERBB2

ERBB2

Basics

Aliases:
This biomarker is also known as:
  • Proto-oncogene c-ErbB-2,
  • NEU,
  • HER-2,
  • Receptor tyrosine-protein kinase erbB-2,
  • CD_antigen=CD340,
  • HER-2/neu,
  • Proto-oncogene Neu,
  • TKR1,
  • Tyrosine kinase-type cell surface receptor HER2,
  • HER2,
  • c-ErbB-2,
  • v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian),
  • v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog),
  • MLN 19,
  • Metastatic lymph node gene 19 protein,
  • p185erbB2,
  • MLN19,
  • NGL,
  • CD340,

View in BioMuta

Description…

ERBB2, often known as HER-2/neu, a single-pass type I membrane protein, is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. It is part of several cell surface receptor complexes. ERBB2 has no ligand binding domain of its own, and needs a coreceptor for ligand binding. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele Ile654/Ile655. There are several transcript variants resulting from alternative splicing events. Some isoforms have not been fully characterized yet.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: ERBB2

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Under Review

Overview

Performance Comment

Ovary

Attributes

Phase: Two
QA State: Under Review

Overview

Amplification and/or overexpression of the ERBB2 gene has been reported in numerous cancers, including breast and ovarian tumors. Studies have suggested that ERBB2 overexpression represented a major negative prognostic indicator for patients with several human cancers, including endometrial carcinomas

Performance Comment

Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 11/20/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.